3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
34
Neoplasm Metastasis
3
Osteoporosis
2
Fractures, Bone
2
Arthralgia
2
Polycystic Ovary Syndrome
1
Neurotoxicity Syndromes
1
Neoplasms, Hormone-Dependent
1
Fatigue
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Carcinoma, Lobular
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Ductal, Breast
1
Breast Neoplasms, Male
1
Breast Carcinoma In Situ
1
Breast Cancer Metastatic
1
Bone Diseases, Metabolic
1
Interventions
Letrozole
3
Fulvestrant
3
exemestane
2
Trastuzumab
2
Irinotecan
2
Docetaxel
2
Capecitabine
2
Anastrozole
2
ribociclib
1
palbociclib
1
irinotecan sucrosofate
1
abemaciclib
1
Rogaratinib
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Liposomes
1
Everolimus
1
Cyclophosphamide
1
Cell Separation
1
Aromatase Inhibitors
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Breast Cancer Metastatic
×
Aromatase Inhibitors
×
Clear all
NCT02511639
2020-12-03
MAIN-A
Istituto Oncologico Veneto IRCCS
Phase 3
Completed
110 enrolled